Cargando…

Exploring the Validity of Available Markers and Indices in the Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) in People with Type 2 Diabetes in Saudi Arabia

Nonalcoholic fatty liver disease (NAFLD) is common among Saudi patients with type 2 diabetes (T2DM). However, recommended clinical procedures to detect it are unavailable in many locations. Therefore, better and more available diagnostic biomarkers for NAFLD are needed. Various serum parameters were...

Descripción completa

Detalles Bibliográficos
Autores principales: Ajabnoor, Ghada M. A., Bahijri, Suhad M., Enani, Sumia Mohammad, Alsheikh, Lubna, Ahmed, Maimoona, Alhozali, Amani, Al-Shali, Khalid, Eldakhakhny, Basmah Medhat, Alamoudi, Aliaa A., Al-Ahmadi, Jawaher, Borai, Anwar, Al-Mowallad, Alaa Salem, Tuomilehto, Jaakko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887592/
https://www.ncbi.nlm.nih.gov/pubmed/36648875
http://dx.doi.org/10.3390/diseases11010010
_version_ 1784880372999258112
author Ajabnoor, Ghada M. A.
Bahijri, Suhad M.
Enani, Sumia Mohammad
Alsheikh, Lubna
Ahmed, Maimoona
Alhozali, Amani
Al-Shali, Khalid
Eldakhakhny, Basmah Medhat
Alamoudi, Aliaa A.
Al-Ahmadi, Jawaher
Borai, Anwar
Al-Mowallad, Alaa Salem
Tuomilehto, Jaakko
author_facet Ajabnoor, Ghada M. A.
Bahijri, Suhad M.
Enani, Sumia Mohammad
Alsheikh, Lubna
Ahmed, Maimoona
Alhozali, Amani
Al-Shali, Khalid
Eldakhakhny, Basmah Medhat
Alamoudi, Aliaa A.
Al-Ahmadi, Jawaher
Borai, Anwar
Al-Mowallad, Alaa Salem
Tuomilehto, Jaakko
author_sort Ajabnoor, Ghada M. A.
collection PubMed
description Nonalcoholic fatty liver disease (NAFLD) is common among Saudi patients with type 2 diabetes (T2DM). However, recommended clinical procedures to detect it are unavailable in many locations. Therefore, better and more available diagnostic biomarkers for NAFLD are needed. Various serum parameters were suggested, and algorithms that employ routine measurements in clinical practice have been developed for the prediction of fat stores in the liver in different populations. However, no such studies have been conducted on Saudis. We aimed to compare selected biochemical markers and calculated indices in T2DM patients diagnosed with NAFLD and patients without NAFLD to find the best markers associated with NAFLD. A cross-sectional study was employed to recruit 67 people with T2DM from endocrine outpatient clinics at King Abdul-Aziz University Hospital. NAFLD was detected by ultrasonography in 28 patients. Demographic information, anthropometric, and blood pressure (BP) measurements were taken. Fasting blood samples were obtained to measure glucose, glycated haemoglobin, lipid profile, liver function tests, and highly sensitive C-reactive protein. Fatty liver index, hepatic steatosis index, NAFLD-liver fat score, and triglyceride and glucose index were calculated. Following stepwise forward likelihood ratio regression with independent variables included in one model using binary logistic regression with age and waist circumference (WC) entered as covariates, elevated diastolic BP and low high-density lipoprotein- cholesterol remained significantly associated with NAFLD (p = 0.002 and 0.03, respectively). However, none of the investigated indices could be used to diagnose the disease adequately due to low specificity, even after calculating new cut-off values. Investigating novel markers and adjusting existing equations used to calculate indices to improve sensitivity and specificity in our population is needed.
format Online
Article
Text
id pubmed-9887592
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98875922023-02-01 Exploring the Validity of Available Markers and Indices in the Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) in People with Type 2 Diabetes in Saudi Arabia Ajabnoor, Ghada M. A. Bahijri, Suhad M. Enani, Sumia Mohammad Alsheikh, Lubna Ahmed, Maimoona Alhozali, Amani Al-Shali, Khalid Eldakhakhny, Basmah Medhat Alamoudi, Aliaa A. Al-Ahmadi, Jawaher Borai, Anwar Al-Mowallad, Alaa Salem Tuomilehto, Jaakko Diseases Article Nonalcoholic fatty liver disease (NAFLD) is common among Saudi patients with type 2 diabetes (T2DM). However, recommended clinical procedures to detect it are unavailable in many locations. Therefore, better and more available diagnostic biomarkers for NAFLD are needed. Various serum parameters were suggested, and algorithms that employ routine measurements in clinical practice have been developed for the prediction of fat stores in the liver in different populations. However, no such studies have been conducted on Saudis. We aimed to compare selected biochemical markers and calculated indices in T2DM patients diagnosed with NAFLD and patients without NAFLD to find the best markers associated with NAFLD. A cross-sectional study was employed to recruit 67 people with T2DM from endocrine outpatient clinics at King Abdul-Aziz University Hospital. NAFLD was detected by ultrasonography in 28 patients. Demographic information, anthropometric, and blood pressure (BP) measurements were taken. Fasting blood samples were obtained to measure glucose, glycated haemoglobin, lipid profile, liver function tests, and highly sensitive C-reactive protein. Fatty liver index, hepatic steatosis index, NAFLD-liver fat score, and triglyceride and glucose index were calculated. Following stepwise forward likelihood ratio regression with independent variables included in one model using binary logistic regression with age and waist circumference (WC) entered as covariates, elevated diastolic BP and low high-density lipoprotein- cholesterol remained significantly associated with NAFLD (p = 0.002 and 0.03, respectively). However, none of the investigated indices could be used to diagnose the disease adequately due to low specificity, even after calculating new cut-off values. Investigating novel markers and adjusting existing equations used to calculate indices to improve sensitivity and specificity in our population is needed. MDPI 2023-01-15 /pmc/articles/PMC9887592/ /pubmed/36648875 http://dx.doi.org/10.3390/diseases11010010 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ajabnoor, Ghada M. A.
Bahijri, Suhad M.
Enani, Sumia Mohammad
Alsheikh, Lubna
Ahmed, Maimoona
Alhozali, Amani
Al-Shali, Khalid
Eldakhakhny, Basmah Medhat
Alamoudi, Aliaa A.
Al-Ahmadi, Jawaher
Borai, Anwar
Al-Mowallad, Alaa Salem
Tuomilehto, Jaakko
Exploring the Validity of Available Markers and Indices in the Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) in People with Type 2 Diabetes in Saudi Arabia
title Exploring the Validity of Available Markers and Indices in the Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) in People with Type 2 Diabetes in Saudi Arabia
title_full Exploring the Validity of Available Markers and Indices in the Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) in People with Type 2 Diabetes in Saudi Arabia
title_fullStr Exploring the Validity of Available Markers and Indices in the Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) in People with Type 2 Diabetes in Saudi Arabia
title_full_unstemmed Exploring the Validity of Available Markers and Indices in the Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) in People with Type 2 Diabetes in Saudi Arabia
title_short Exploring the Validity of Available Markers and Indices in the Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) in People with Type 2 Diabetes in Saudi Arabia
title_sort exploring the validity of available markers and indices in the diagnosis of nonalcoholic fatty liver disease (nafld) in people with type 2 diabetes in saudi arabia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887592/
https://www.ncbi.nlm.nih.gov/pubmed/36648875
http://dx.doi.org/10.3390/diseases11010010
work_keys_str_mv AT ajabnoorghadama exploringthevalidityofavailablemarkersandindicesinthediagnosisofnonalcoholicfattyliverdiseasenafldinpeoplewithtype2diabetesinsaudiarabia
AT bahijrisuhadm exploringthevalidityofavailablemarkersandindicesinthediagnosisofnonalcoholicfattyliverdiseasenafldinpeoplewithtype2diabetesinsaudiarabia
AT enanisumiamohammad exploringthevalidityofavailablemarkersandindicesinthediagnosisofnonalcoholicfattyliverdiseasenafldinpeoplewithtype2diabetesinsaudiarabia
AT alsheikhlubna exploringthevalidityofavailablemarkersandindicesinthediagnosisofnonalcoholicfattyliverdiseasenafldinpeoplewithtype2diabetesinsaudiarabia
AT ahmedmaimoona exploringthevalidityofavailablemarkersandindicesinthediagnosisofnonalcoholicfattyliverdiseasenafldinpeoplewithtype2diabetesinsaudiarabia
AT alhozaliamani exploringthevalidityofavailablemarkersandindicesinthediagnosisofnonalcoholicfattyliverdiseasenafldinpeoplewithtype2diabetesinsaudiarabia
AT alshalikhalid exploringthevalidityofavailablemarkersandindicesinthediagnosisofnonalcoholicfattyliverdiseasenafldinpeoplewithtype2diabetesinsaudiarabia
AT eldakhakhnybasmahmedhat exploringthevalidityofavailablemarkersandindicesinthediagnosisofnonalcoholicfattyliverdiseasenafldinpeoplewithtype2diabetesinsaudiarabia
AT alamoudialiaaa exploringthevalidityofavailablemarkersandindicesinthediagnosisofnonalcoholicfattyliverdiseasenafldinpeoplewithtype2diabetesinsaudiarabia
AT alahmadijawaher exploringthevalidityofavailablemarkersandindicesinthediagnosisofnonalcoholicfattyliverdiseasenafldinpeoplewithtype2diabetesinsaudiarabia
AT boraianwar exploringthevalidityofavailablemarkersandindicesinthediagnosisofnonalcoholicfattyliverdiseasenafldinpeoplewithtype2diabetesinsaudiarabia
AT almowalladalaasalem exploringthevalidityofavailablemarkersandindicesinthediagnosisofnonalcoholicfattyliverdiseasenafldinpeoplewithtype2diabetesinsaudiarabia
AT tuomilehtojaakko exploringthevalidityofavailablemarkersandindicesinthediagnosisofnonalcoholicfattyliverdiseasenafldinpeoplewithtype2diabetesinsaudiarabia